Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06669117 · ClinicalTrials.gov registry record · Phase 1
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
A Phase 1 study of Solid Tumor and MET Alteration, sponsored by Pierre Fabre Medicament.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 19
- Study locations
NCT06669117: Recruiting Phase 1 study of Solid Tumor and MET Alteration, sponsored by Pierre Fabre Medicament.
NCT06669117 is a Phase 1 study of Solid Tumor and MET Alteration that is actively recruiting participants, run by Pierre Fabre Medicament. The registered enrollment target is 140 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower). The trial reports 19 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06669117, a Phase 1 study of Solid Tumor and MET Alteration, is actively recruiting participants, sponsored by Pierre Fabre Medicament.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 19
- Study locations
Study Summary
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG VERT-002
Study Locations (19)
Other
- Institut Jules Bordet - Anderlecht
- APHP de Marseille - Hôpital Nord - Marseille
- Institut de Cancerologie de Ouest (ICO) - Saint-Herblain - Saint-Herblain
- Institut Universitaire du Cancer de Toulouse - Oncopole - Toulouse
- Gustave Roussy - Villejuif
- Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO) - Cologne
- Universitätsklinikum Carl Gustav Carus Dresden - Dresden
- Azienda Ospedaliero - Universitaria San Luigi Gonzaga - Orbassano
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis - Amsterdam
- Yonsei University College of Medicine - Seoul
- Asan Medical Center (AMC) - Seoul
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario La Paz - Madrid
- National Taiwan University Hospital - Taipei
- Taipei Medical University Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
Ohio
- Gabrail Cancer Research Center - Canton
Tennessee
- Sarah Cannon Research Institute Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 1 |
What NCT06669117 shows while recruiting
NCT06669117 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which VERT-002 is the first listed.
NCT06669117 lists 19 locations in 4 states (Other, District of Columbia, Ohio).
Frequently Asked Questions
What is clinical trial NCT06669117 about?
NCT06669117 is a clinical study titled "FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations". The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
What is the current status of trial NCT06669117?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2024-10-22. Estimated completion is 2032-10-01.
What conditions does trial NCT06669117 study?
This clinical trial studies the following conditions: Solid Tumor, MET Alteration.
What interventions are being tested in trial NCT06669117?
The interventions under investigation include: VERT-002 (DRUG).
Who is sponsoring clinical trial NCT06669117?
This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06669117 being conducted?
This trial has 19 study locations across District of Columbia, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06669117's enrollment target sits among peer trials
140 63rd of 196 higher than 132 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI